UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of **January 2022**

Commission File Number: **001-36187**

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot
P.O.B 4173, Ness Ziona, 7414002, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

CONTENTS

On January 18, 2022, Evogene Ltd., or Evogene, announced positive results in pre-clinical studies in the Precise product program for medical cannabis of its subsidiary Canonic Ltd., or Canonic. A copy of the press release is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K, or this Form 6-K, and is incorporated herein by reference.

In addition, an updated Canonic investor presentation is furnished as Exhibit 99.2 to this Form 6-K.

The contents of Exhibit 99.1 to this Form 6-K, excluding the statements of Canonic's CEO and of its advisor, are incorporated by reference into the registration statements on Form F-3 (File No. 333-253300) and on Form S-8 (File Nos. 333-193788, 333-201443, 333-203856 and 333-259215) of Evogene, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.
(Registrant)

Date: January 18, 2022

By: /s/ Dorit Kreiner
_____

Dorit Kreiner
Chief Financial Officer

EXHIBIT INDEX

Exhibit 99.1

Canonic Announces Positive Results in Pre-Clinical Studies in its *Precise* Product Program for Medical Cannabis

The results support the successful identification of specific cannabis varieties with anti-inflammatory and pain relief properties, for which Canonic recently filed a patent application

Rehovot, Israel – January 18, 2022 – Canonic Ltd., focused on the development of medical grade cannabis products and a wholly-owned subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), announced today positive results in pre-clinical studies in inflammatory and pain model systems conducted in Israel by **Hadassah Medical Center** in Jerusalem and by **Migal - Galilee Research Institute** in Kiryat Shmona. The results support the identification of specific cannabis varieties with heightened anti-inflammatory and pain relief properties for Canonic's medical cannabis *Precise* product line and have led to a patent application filing.

In its *Precise* product line, Canonic aims to develop medical grade cannabis inflorescence and oil products that provide relief for patients for specific medical indications with a high level of consistency and specificity in its clinical effects. Canonic's first product candidates within the *Precise* program target pain relief and inflammation reduction and are planned to be launched in Israel during 2023, followed by a European expansion.

According to industry estimates, the medical cannabis market in Europe is estimated to pass €1 billion in 2023. According to a broad health economic study run by the BfArM[1] conducted in Germany, which represents over 50% of the European market, pain relief was the most frequently treated medical indication representing more than 70% of the medical indications treated with medical cannabis or cannabis-based medicines[2]. The Israeli medical cannabis market includes over 105,000 licensed patients and is estimated at $260 million per year, with over 60% of medical cannabis in Israel prescribed for pain and inflammation indications[3].

---

[1] The Federal Institute for Drugs and Medical Devices in Germany (https://www.bfarm.de/EN/Home/_node.html)

[2] https://pubmed.ncbi.nlm.nih.gov/33564897/; https://www.aerzteblatt.de/int/archive/article/218127/Interim-results-of-the-survey-accompanying-the-prescription-of-cannabis-based-medicines-in-Germany-regarding-dronabinol

[3] Please note the sources are in Hebrew: https://www.health.gov.il/Subjects/cannabis/Documents/licenses-status-december-2021.pdf; https://finance.walla.co.il/item/3428846

In the pre-clinical studies reported today, Canonic screened multiple cannabis lines from its diverse genetic collection for anti-inflammatory and pain relief properties. These lines had been selected according to active compounds compositions by using Evogene's *GeneRator AI* tech engine. The screening of these selected lines was conducted in two separate models – in an *in-vitro* model at the laboratory of Prof. Reuven Or at the Hadassah Medical Center and in an *in-vivo* (fish larvae) model at Migal - Galilee Research Institute. Several varieties, including the cannabis variety which is the basis for Canonic's product G150[4], exhibited consistent positive results in both model systems, over several repetitions and independent cultivation cycles. Based on these results, Canonic has filed a patent application for several of these cannabis varieties and their medical effects.

Canonic expects to continue the development of these best performing varieties during 2022, including the gathering of clinical data, in expectation of commercializing its first *Precise* products in 2023 in Israel, with expansion into Europe planned to follow.

Canonic recently strengthened its management team with the recruitment of Ms. Tanya Damm Bokobza, EVP Business Development, and Dr. Haleli Sharir, Clinical Research Director. Their engagement with Canonic will support the plans for commercial expansion in Israel and Europe and clinical research activities. Canonic also published an updated investor presentation, which can be found here[5].

Prof. Yossi (Joseph) Tam, Managing Director of the Multidisciplinary Center for Cannabinoid Research at the Hebrew University of Jerusalem & Advisor to Canonic, stated: "We would all like to think that cannabis represents a potential solution for specific, difficult to treat, medical conditions, such as pain or inflammatory diseases, for which we lack ideal treatments. After all, it would be poetic if nature's wisdom provided the medicine we have not yet designed ourselves. The ability of Canonic's medical cannabis varieties in reducing pain and inflammation in pre-clinical settings is impressive. Indeed, breeding whole cannabis plants such that they contain specific compounds in specific quantities and tailored ratios in order to hit the right disease targets with minimal adverse events is what we should aim for in order to benefit our society. And this is exactly what Canonic does."

---

[4] For more information, please see: https://canonic.co.il/g150/. Please note that the page is in Hebrew.
[5] http://www.evogene.com/wp-content/uploads/2022/01/Canonic-Company-Presentation_Jan2022_FINAL.pdf

Dr. Arnon Heyman, CEO of Canonic, stated: "We are pleased with the progress achieved in these pre-clinical studies, which now allow us to advance the development of our first products in the *Precise* medical cannabis line. These results demonstrate further confirmation for the power of the computational biology platform that we use, supported by Evogene's *GeneRator AI* tech engine. I would like to thank our partners at Hadassah Medical Center and Migal - Galilee Research Institute and I look forward to continuing the development of our novel products. I believe that the global cannabis market is moving in the direction of products backed by clinical data supporting the consistency of medical relief for patients. These are precisely the type of products Canonic is developing in its *Precise* program. We look forward to updating as we advance towards commercialization."

About Canonic Ltd.:

Canonic is a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), developing medical Cannabis products utilizing a Computational Predictive Biology (CPB) platform. The Company's products in development are aimed at improving active compounds yield, genetic stability and Cannabis varieties for specific medical indications. The Company's strategy includes the development of Cannabis varieties in order to commercialize medical Cannabis products independently or through collaborations. Canonic has exclusive access to Evogene's genomic assets and technology for the development of medical Cannabis products. **For more information, please visit:** https://www.canonicbio.com/.

About Evogene Ltd.:

Evogene (NASDAQ: EVGN, TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil production through Casterra Ag. Ltd. **For more information, please visit:** www.evogene.com.

Forward Looking Statements:

Evogene Investor Contact:

Rivka Neufeld
Investor Relations
E: IR@evogene.com
T: +972-8-931-1940

US Investor Relations:

Joseph Green
Edison Group
E: jgreen@edisongroup.com
T: +1 646-653-7030

Laine Yonker
Edison Group
E: lyonker@edisongroup.com
T: +1 646-653-7035

Exhibit 99.2

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and Canonic Ltd (the "Company") and its parent, Evogene Ltd. ("Evogene"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

# INTRODUCTION

CANONIC
CULTIVATED BY SCIENCE

OUR VISION

Commercialize effective, precise and stable medical cannabis products, based on decoding plant genetics, for optimized therapeutic effect

CANONIC

Global Cannabis Market

Legal Cannabis Worldwide: $46.8 Billion in 2025

Market Challenges

STABILITY

Substantial variations within varieties produce inconsistent products and therefore, inconsistent results

YIELD

Low yield of active compounds affects income per sq foot

SPECIFICITY

Significant knowledge gap prevents matching active compounds to medical indications

The opportunity : With state-of-the-art plant genomic expertise, major market challenges can be solved

CANONIC

The opportunity
From Plant Genetics – To Medical Cannabis Products

Plant genetics know-how is the basis for development of **premium Cannabis varieties**

Premium varieties can lead to **novel medical Cannabis products** addressing market challenges

PRODUCTS

Variety Families Under Development

MetaYield+

Stable enhancement of **total plant** compounds

Focus on **agronomic** and **consumer** traits

Increased active compounds
[e.g. Increased trichomes prevalence]

Optimize consumer traits
[e.g. inflorescence size, density, scent]

First products in the market

Precise+

Stable enhancement of **specific active** compounds

Focus on **therapeutic** traits

Medical indication focus
[e.g. Pain & Inflammation]

Compound profile focus
[e.g. CBG, CBC]

Next generation products

CANONIC

MetaYield⁺ Varieties – The G-nnovation series

Now available in more than 70 pharmacies in Israel

Product 1: G150

Scent
Pine
Lemon

Use
Day

IMC* category T15C3

18 % THC

High consumer rank

Active compounds
THC18%,CBD>0.1

Product 2: G200

Scent
Pine
Sweet

Use
Night

IMC* category T20C4

21 % THC

High consumer rank

Active compounds
THC21%,CBD>0.1

*IMC- Israel Medical Cannabis agency in the Ministry of Health

△ CANONIC

Precise⁺: Medical indication focus

PRODUCT 1 (under development)

Indication: Inflammation

Pre-clinical study: Hadassah medical center

Status: product development

Expected launch: 2023

Target market size in 2023*: Israel $115M, EU $300M

PRODUCT 2 (under development)

Indication: Pain

Pre-clinical study: Migal research center

Status: product development

Expected launch: 2023

Target market size in 2023*: Israel $280 M, EU $750M

Hadassah Medical Center

MIGAL Galilee Research Institute LTD.

*Company estimate, based on current market sale prices and data published by Israeli Ministry of Health regarding number of medical cannabis users in Israel and by Prohibition Partners in The European Cannabis Report Feb 2020.

CANONIC

Precise⁺: Specific compound profile

PRODUCT 3 (under development)

- ⬣ **Targeting specific compound profile**
- ⬣ **Pre-clinical study:** under evaluation
- ⬣ **Status:** product development

Collaboration With Tikun Olam-Cannbit

TIKUN ❀ OLAM
MEDICAL CANNABIS
CANNBIT PHARMACEUTICALS LTD

The Genomic Power – improving performance

The potential:
Improving plant traits through advanced breeding

Example –

Corn is considered a leading commercial crop

Wild corn went through genetic changes before it became a commercial crop.

The challenge:

Connect genomic elements to traits

Shorten the development time

The opportunity => BIG DATA AND
COMPUTATIONAL BIOLOGY

Wild Maze

Cultured Maze

When Data Meets Computational Biology

Computational Genomics

Combining deep scientific know-how with Big Data and AI technology to tailor the plant genetics for improvement of plant traits and development of unique cannabis products

BIG DATA

Genomics

AI

Canonic proprietary database and assets

>1000 characterized lines ($>17.5 \times 10^6$ data points)

Genotype

Phenotype

Chemotype

Pre-clinical

Accumulated assets

Genetic bank
'Mother' plants,
seeds,
tissue culture

Genetic markers
For traits of interest
(e.g. active compounds)

Diverse Breeding populations
Proprietary hybrids

Big Data & AI transforming Data to Know-how

Plant genomics
database with >10^9
data points on > 200
plants

Proprietary
Cannabis genomic &
chemical data on >
1000 lines

Pre-clinical
data

BIG DATA

Gene
Rator AI

Computational
**genomics tools**

AI

Products

CANONIC

The genomic power – 20% increase in THC content

Developing next generation MetaYield+ products

By leveraging our unique proprietary know-how and database, within 12 months we have:

- Improved the target trait by 20%
- Reached 6-fold increase in number of cannabis lines with >20% THC content

△ CANONIC

Demonstrated Capabilities Along The Development Value Chain

Canonic holds computational genomics capabilities and the full plant infrastructure to execute

Large genetic & breeding collections

State of the art data collection tools

World-class computational genomics

Advanced-breeding facility

Fully equipped labs & tissue culture rooms

Certified Propagation farm

BUSINESS MODEL

Cannabis Value Chain

Seed to Sale Powered by Genomics

ACTIVITY

Varieties Development	Seeds & Seedling Production	Cannabis Cultivation	Manufacturing	Distribution	Sales & Marketing	Patients
R&D Facilities	Propagation Farms	Cultivators	Extraction & Formulation	Regional Distributors	B2B2C marketing to Pharmacies	

Canonic in the Cannabis Value Chain

Reduced time to market and higher profitability by leveraging our proprietary genomic expertise and outsourcing downstream elements of the value chain

SUMMARY

Team

Dr. Arnon Heyman

CEO

Tanya Damm Bokobza

EVP Business Development

Dr. Inbal Dangoor

VP R&D

Guy Adler

VP Product

Elena Huly

Marketing & Sales

Yonatan Wegman

Head Agronomist

Dr. Michi Brog

Plant Breeder

Dr. Haleli Sharir

Clinical Research Director

CANONIC

Directors and Advisory Board

Board of directors

Ofer Haviv
Chairman of the board

Evogene President & CEO

Raanan Cohen
Business strategy

Former CEO Koor Industries

Dorit Kreiner
Finance

Evogene CFO

Advisory board

Prof. Yossi Tam
Cannabinoid clinical research

Director, Multidisciplinary Center for Cannabinoid Research of the Hebrew University

Nirit Elyovich
Marketing strategy

Senior marketing specialist with over 20 years of B2C experience

Omri Ofer
Pharmaceutical distribution

Former CEO Chemipal

Dr. Yariv Brotman
Plant metabolic pathways

Ben Gurion University & Max Planck Institute of Molecular Plant Physiology

Shai Leviatov
Plant breeding

Commercial varieties breeding for more than 30 years in top leading multinational seeds companies

CANONIC

Company Milestones

Summary

- **Canonic's distinct market advantage** is in mapping, decoding and stabilizing cannabis genetics for better health.

- Canonic holds exclusive rights to Evogene's (NASDAQ, TASE: EVGN) state-of-the-art **computational genomics technology,** for product development for the Cannabis market segment.

- **Canonic's first two products, G-150 and G-200,** were launched in Israel in October 2021.

- Next generation products are expected to focus on 2 major medical indications, **pain and inflammation**, which represent > 60% of the medical market*.

- Canonic aims to enter the EU market during 2023.

*Company estimate, based on data published by Israeli Ministry of Health regarding number of medical cannabis users in Israel

⟨△⟩ CANONIC